Metformin osmotic
Searched over 200M research papers for "metformin osmotic"
Research Analysis by Consensus
Beta · 20 papersConsensus Meter
Yes%
Possibly%
No%
Metformin Osmotic Delivery Systems: Innovations and Efficacy
Introduction to Metformin Osmotic Delivery
Metformin hydrochloride (MH) is a widely used medication for managing type 2 diabetes mellitus. However, its short half-life necessitates multiple daily doses, leading to patient inconvenience and fluctuating plasma concentrations. Recent advancements in osmotic delivery systems aim to address these issues by providing controlled and sustained release of metformin, thereby improving patient compliance and therapeutic outcomes.
Sandwiched Osmotic Pump Tablets for Metformin and Repaglinide
A novel sandwiched osmotic pump tablet has been developed to deliver metformin hydrochloride and repaglinide simultaneously at a zero-order rate. This system separates the two drugs into different layers with a push layer in between, ensuring controlled release over 12 and 8 hours, respectively. Pharmacokinetic studies in beagle dogs demonstrated a significantly decreased Cmax, prolonged Tmax, and satisfactory bioavailability, indicating a promising alternative to conventional multidrug therapy for type 2 diabetes.
Enteric Osmotic Pump Capsules for Enhanced Bioavailability
Another innovative approach involves the development of enteric osmotic pump capsules (EOPC) designed to deliver metformin directly to the small intestine. This system uses an enteric semipermeable capsule shell and core prescription fillers optimized through single factor tests. The EOPC demonstrated sustained and stable drug release in vitro, aligning with the zero-order model, and achieved higher bioavailability compared to commercial enteric capsules and sustained release tablets. This method potentially reduces adverse reactions and improves patient compliance.
Controlled Release of Metformin and Gliclazide
A sandwiched osmotic pump capsule has also been designed to deliver metformin hydrochloride and gliclazide simultaneously. This system addresses the issues of short half-life and burst release by filling the drugs on either side of a push layer. Pharmacokinetic studies in beagle dogs showed decreased Cmax, prolonged Tmax, and improved bioavailability, independent of pH and agitation speed, making it a promising substitute for conventional products.
Elementary Osmotic Pump Tablets for Metformin and Glipizide
Elementary osmotic pump (EOP) systems have been developed to deliver metformin and glipizide simultaneously. These systems use sodium carbonate to modulate the solubility of glipizide and metformin as an osmotic agent. The optimized EOP delivers both drugs at a zero-order rate for up to 10 hours, demonstrating good sustained release in vivo compared to conventional tablets. Another study confirmed the effectiveness of an inlay osmotic pump tablet (IOPT) that releases glipizide rapidly within 2 hours and metformin in a sustained manner up to 12 hours, further enhancing the multidrug therapy for diabetes.
Critical Factors in Metformin Osmotic Pump Design
Key factors influencing the design of metformin osmotic pumps include the concentration of hydrophilic polymers, the diameter of the drug-releasing orifice, and coating thickness. These factors significantly impact the drug release profile, ensuring a constant release rate over 24 hours. The developed systems demonstrated linear release rates and were independent of agitation intensity and gastrointestinal pH, highlighting their robustness and reliability.
Conclusion
Osmotic delivery systems for metformin, whether in combination with other antidiabetic drugs or as standalone treatments, offer significant advantages over conventional formulations. These systems provide controlled and sustained drug release, improve bioavailability, and enhance patient compliance. Continued research and optimization of these delivery systems hold promise for more effective and convenient diabetes management.
Sources and full results
Most relevant research papers on this topic
